Dr. Reardon on Updated Data From the Phase II ReACT Trial

David Reardon, MD
Published: Friday, Nov 20, 2015

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma. Reardon presented these data at the 2015 Annual Meeting of the Society for Neuro-Oncology (SNO).

At the 2015 ASCO Annual Meeting, Reardon and his colleagues reported a survival benefit with the combination, though the data were not fully mature.

Reardon says that at the SNO meeting, he is reporting data that show that the survival benefit is increased and enhanced. In fact, the 2-year survival rate in the trial was 25% with rindopepimut compared with 0% for patients treated in the control arm.

<<< View more from the 2015 SNO Meeting

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma. Reardon presented these data at the 2015 Annual Meeting of the Society for Neuro-Oncology (SNO).

At the 2015 ASCO Annual Meeting, Reardon and his colleagues reported a survival benefit with the combination, though the data were not fully mature.

Reardon says that at the SNO meeting, he is reporting data that show that the survival benefit is increased and enhanced. In fact, the 2-year survival rate in the trial was 25% with rindopepimut compared with 0% for patients treated in the control arm.

<<< View more from the 2015 SNO Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x